Pyoderma gangrenosum - Pipeline Insight, 2024

This “Pyoderma gangrenosum - Pipeline Insight, 2024,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Pyoderma gangrenosum pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Pyoderma gangrenosum Understanding

Pyoderma gangrenosum: Overview

Pyoderma gangrenosum (PG) is an inflammatory skin disorder that is characterized by small, red bumps or blisters (papules or nodules) that eventually erode to form swollen open sores (ulcerations). The size and depth of the ulcerations vary greatly, and they are often extremely painful. In approximately 50 percent of cases, PG occurs secondary to another disorder such as inflammatory bowel disease. The exact cause of PG is unknown (idiopathic). Some researchers believe it may be an autoimmune disorder.

Pyoderma gangrenosum - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pyoderma gangrenosum pipeline landscape is provided which includes the disease overview and Pyoderma gangrenosum treatment guidelines. The assessment part of the report embraces, in depth Pyoderma gangrenosum commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pyoderma gangrenosum collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Pyoderma gangrenosum R&D. The therapies under development are focused on novel approaches to treat/improve Pyoderma gangrenosum.

Pyoderma gangrenosum Emerging Drugs Chapters

This segment of the Pyoderma gangrenosum report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pyoderma gangrenosum Emerging Drugs

Vilobelimab: InflaRx InflaRx's lead drug candidate, vilobelimab (IFX-1), is a first-in-class monoclonal antibody targeting the complement activation product C5a and is currently in clinical development for several indications including Pyoderma Gangraenosum (PG), a rare ulcerative skin disorder. InflaRx is currently conducting a Phase II clinical study to investigate a potential benefit of vilobelimab (IFX-1) for patients suffering fromPG.

Ixekizumab: Eli Lilly and Company Ixekizumab is a humanized IgG4 monoclonal antibody developed by Eli Lilly & Company for the treatment of autoimmune diseases. It was designed specifically to bind interleukin-17A (IL-17A) and produced by recombinant DNA technology in a recombinant mammalian cellline.

Pyoderma gangrenosum: Therapeutic Assessment

This segment of the report provides insights about the different Pyoderma gangrenosum drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Pyoderma gangrenosum

There are approx. 3+ key companies which are developing the therapies for Pyoderma gangrenosum. The companies which have their Pyoderma gangrenosum drug candidates in the most advanced stage, i.e. phase II include, InflaRx.

Phases

This report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Pyoderma gangrenosum pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pyoderma gangrenosum: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pyoderma gangrenosum therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pyoderma gangrenosum drugs.

Pyoderma gangrenosum Report Insights

• Pyoderma gangrenosum Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Pyoderma gangrenosum Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Pyoderma gangrenosum drugs?
• How many Pyoderma gangrenosum drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pyoderma gangrenosum?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pyoderma gangrenosum therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pyoderma gangrenosum and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• InflaRx
• Aclaris Therapeutics
• Eli Lilly and Company
• Novartis

Key Products

• Vilobelimab
• ATI 450
• Ixekizumab

Research programme: mitogen-activated protein kinase-activated protein kinase-2 pathway inhibitors- Secukinumab


This product will be delivered within 2 business days.